Evidence map›Paper›PMID 41820396›Full record

ArticleNature communications2026

Multimodal framework for the joint analysis of single-cell RNA and T cell receptor sequencing data predicts T cell response to cancer immunotherapy.

Chujun He, Matthew Amodio, Orr Ashenberg, Kai W Wucherpfennig, Ramnik J Xavier, Caroline Uhler

Abstract read
In one paragraph

Article in Nature communications, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Chujun He *Eric and Wendy Schmidt Center, Broad Institute of MIT and Harvard, Cambridge, MA, USA.
Matthew Amodio *Eric and Wendy Schmidt Center, Broad Institute of MIT and Harvard, Cambridge, MA, USA.
Orr AshenbergEric and Wendy Schmidt Center, Broad Institute of MIT and Harvard, Cambridge, MA, USA. orr@broadinstitute.org.
Kai W WucherpfennigDepartment of Cancer Immunology and Virology, Dana-Farber Cancer Institute, Boston, MA, USA.ORCID http://orcid.org/0000-0002-1829-302X
Ramnik J XavierKlarman Cell Observatory, Broad Institute of MIT and Harvard, Cambridge, MA, USA. rxavier@broadinstitute.org.
Caroline UhlerEric and Wendy Schmidt Center, Broad Institute of MIT and Harvard, Cambridge, MA, USA. cuhler@mit.edu.ORCID http://orcid.org/0000-0002-7008-0216

Funding

Understanding and Overcoming T cell Immunosuppression in GlioblastomaP01CA236749 · NCI · BRIGHAM AND WOMEN'S HOSPITAL · PI Mario Luca Suva · 2020 to 2026
$19.5M
Causal Representation Learning for the Spatial Analysis of Transcriptomic and Imaging Data in Tissue ContextsDP2AT012345 · NCCIH · BROAD INSTITUTE, INC. · PI UHLER, CAROLINE · 2022 to 2025
$2.3M
DOE | Advanced Research Projects Agency - Energy (Advanced Research Projects Agency - Energy - U.S. Department of Energy) DE- SC002318NCCIH NIH HHS DP2 AT012345NCI NIH HHS P01 CA236749Simons Foundation Simons Investigator AwardUnited States Department of Defense | United States Navy | Office of Naval Research (ONR) N00014-24-1-268United States Department of Defense | United States Navy | ONR | Office of Naval Research Global (ONR Global) N00014-24-1-268U.S. Department of Health & Human Services | NIH | National Center for Complementary and Integrative Health (NCCIH) 1DP2AT012345U.S. Department of Health & Human Services | NIH | NCI | Division of Cancer Epidemiology and Genetics, National Cancer Institute (National Cancer Institute Division of Cancer Epidemiology and Genetics) P01 CA16322U.S. Department of Health & Human Services | NIH | NCI | Division of Cancer Epidemiology and Genetics, National Cancer Institute (National Cancer Institute Division of Cancer Epidemiology and Genetics) R01 CA23803
6 · The paper itself

Abstract

T cell states are prognostic in different cancer types. Recent technologies enable joint profiling of T cell RNA and T cell receptor (TCR) sequences at single-cell resolution. Here we present the TCR-RNA Integrating Model (TRIM), a multi-modal variational autoencoder framework that integrates RNA-TCR data and predicts T cell clonality and transcriptional states. TRIM learns a shared representation of the data conditioned on patient, tissue source, and treatment timepoint. We applied TRIM to three independent datasets that included T cells collected before and after checkpoint inhibitor treatment, sourced either from blood and tumor biopsies in patients with head and neck squamous cell carcinoma and colorectal cancer, or from tumor and adjacent tissue in a pan-cancer dataset. In all settings, TRIM accurately predicted intra-tumor T cell clonal expansion and transcriptional status based on T cells from blood or normal tissue before treatment, demonstrating its utility in modeling multimodal T cell data and predicting T cell response to treatment and disease progression.

Indexed as

ImmunotherapyNeoplasmsReceptors, Antigen, T-CellSingle-Cell AnalysisT-LymphocytesAutoencoderColorectal NeoplasmsHead and Neck NeoplasmsHumansImmune Checkpoint InhibitorsSequence Analysis, RNASingle-Cell Gene Expression AnalysisImmune Checkpoint InhibitorsReceptors, Antigen, T-Cell

Identifiers

PMID41820396
PMCPMC13121706

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.